| Patents for A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics (179,784) |
|---|
| 09/12/2003 | WO2003037268A3 Hepta-, octa- and nonapeptides having antiangiogenic activity |
| 09/12/2003 | WO2003022294A3 Extract obtainable from artemisia abrotanum l. (southernwood) |
| 09/12/2003 | WO2003011893A3 Immunologically significant herpes simplex virus antigens and methods for using same |
| 09/12/2003 | WO2003007935A3 Use of a class of antiviral compounds for production of an agent for the treatment or prevention of a viral infection in the respiratory tract |
| 09/12/2003 | WO2003007794A3 Invasion complex and methods of targeting |
| 09/12/2003 | WO2003006612A3 Production of transduced hematopoietic progenitor cells |
| 09/12/2003 | WO2003003017A3 Use of transcription factor nak-1 or genes regulated by transcription factor nak-1 for the diagnosis and/or therapy of inflammatory and malignant diseases |
| 09/12/2003 | WO2003002522A3 Peptide deformylase inhibitors |
| 09/12/2003 | WO2002102835A3 Novel antimicrobial compounds |
| 09/12/2003 | WO2002080979A3 Conjugate of hydroxyalkyl starch and an active agent |
| 09/12/2003 | WO2002080966A3 Method for producing a vaccine containing autologous antibodies |
| 09/12/2003 | WO2002075507A3 Anti-bacterial vaccine compositions |
| 09/12/2003 | WO2002058695A9 (halo-benzo carbonyl)heterocyclo fused phenyl p38 kinase inhibiting agents |
| 09/12/2003 | WO2002040486A3 METHODS OF TREATING p38 KINASE-ASSOCIATED CONDITIONS AND PYRROLOTRIAZINE COMPOUNDS USEFUL AS KINASE INHIBITORS |
| 09/12/2003 | WO2002028424A9 Kyberdrug as autovaccines with immune-regulating effects |
| 09/12/2003 | WO2002028362A3 Vaccine composition and stabilisation method |
| 09/12/2003 | WO2002004443A3 Heterocycle carboxamides as antiviral agents |
| 09/12/2003 | WO2001095785A3 Modulation of immune response and methods based thereon |
| 09/12/2003 | WO2001090197A9 Synthetic peptides and uses therefore |
| 09/12/2003 | WO2001090064A3 COMPOSITION AND METHOD CONTAINING PRODUCTS EXTRACTED FROM COMMIPHORA Sp. FOR PREVENTION AND TREATMENT OF ABNORMAL CELL GROWTH AND PROLIFERATION IN INFLAMMATION, NEOPLASIA AND CARDIOVASCULAR DISEASE |
| 09/12/2003 | CA2478618A1 Isoquinoline derivatives |
| 09/12/2003 | CA2478133A1 Anti-infective agents and/or immunomodulators used for preventive therapy following an acute cerebrovascular accident |
| 09/12/2003 | CA2478042A1 Methods of screening apoptosis modulating compounds, compounds identified by said methods and use of said compounds as therapeutic agents |
| 09/12/2003 | CA2478011A1 Bispecific antibody point mutations for enhancing rate of clearance |
| 09/12/2003 | CA2477795A1 Nucleoside 5'-monophosphate mimics and their prodrugs |
| 09/12/2003 | CA2477449A1 Aminoalkylphosphonates and related compounds as edg receptor agonists |
| 09/12/2003 | CA2477423A1 Aminoalkylphosphonates and related compounds as edg receptor agonists |
| 09/12/2003 | CA2455447A1 Rna interference mediated inhibition of gene expression using short interfering nucleic acid (sina) |
| 09/11/2003 | WO2003074500A2 N-aminoacetyl-pyrrolidine-2-carbonitriles and their use as ddp-iv inhibitors |
| 09/11/2003 | WO2003074054A1 Ophthalmic composition comprising ascomycin |
| 09/11/2003 | US20030172389 Surfactant protein D for the prevention and diagnosis of pulmonary emphysema |
| 09/11/2003 | US20030171587 Antimicrobial 2-pyridones, their compositions and uses |
| 09/11/2003 | US20030171577 Intermediates in cephalosporin production |
| 09/11/2003 | US20030171564 Novel argS |
| 09/11/2003 | US20030171538 Peptides for inducing cytotoxic T lymphocyte responses to hepatitis B virus |
| 09/11/2003 | US20030171425 Viricides |
| 09/11/2003 | US20030171416 Nordihydroguaiaretic acid; anticancer agents, viricides |
| 09/11/2003 | US20030171409 Novel delta dicarbonyl compounds and methods for using the same |
| 09/11/2003 | US20030171406 Medicinal compositions containing propenone derivatives |
| 09/11/2003 | US20030171404 Use of sulfonyl aryl or heteroaryl hydroxamic acids and derivatives thereof as aggrecanase inhibitors |
| 09/11/2003 | US20030171400 Rheumatic diseases; osteoporosis; multiple sclerosis; autoimmune disease; joint replacements |
| 09/11/2003 | US20030171380 Substituted pyrazinones, pyridines and pyrimidines as corticotropin releasing factor ligands |
| 09/11/2003 | US20030171374 Viricides; prevent reproduction of human T-Cell lymphocyte virus |
| 09/11/2003 | US20030171372 Antiviral methods and compounds |
| 09/11/2003 | US20030171366 Having antibacterial activity against Gram-positive and Gram-negative bacteria |
| 09/11/2003 | US20030171363 Non-nucleoside reverse transcriptase inhibitors |
| 09/11/2003 | US20030171359 Suitable for treatment of illnesses characterised by excessive or abnormal cell proliferation; viral, bacterial, fungal and/or parasitic infections, skin diseases, bone diseases, cardiovascular diseases |
| 09/11/2003 | US20030171357 Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| 09/11/2003 | US20030171342 Novel 16-ene-C25-oxime and 16-ene- C-25-oxime ether analogs of 1 alpha ,25-dihydroxy vitamin D3, compositions comprising these compounds and methods of using these compounds as inhibitors of CYP24. |
| 09/11/2003 | US20030171340 Treating antibiotic-resistant infections with a metal complex of tetracycline, glycylcycline, or quinolone antibiotics, or administering a metal compound and the antibiotic together for in situ formation of the complex |
| 09/11/2003 | US20030171337 Useful in the treatment and prophylaxis of inflammatory conditions or in the amelioration of symptoms resulting from or facilitated by an inflammatory condition in a mammalian animal including human and primate, non-mammalian animal and |
| 09/11/2003 | US20030171335 Antisense antiviral agent and method for treating ssRNA viral infection |
| 09/11/2003 | US20030171331 Oxazolidinone cotherapy |
| 09/11/2003 | US20030171330 Antibacterial compound |
| 09/11/2003 | US20030171318 Methods for inhibiting virus propagation and treating virus infection are provided which include administering to cells infected with viruses a compound capable of inhibiting viral budding from the cells. |
| 09/11/2003 | US20030171317 Methods and compositions for reducing bacterial tolerance to antibacterials, disinfectants and organic solvents |
| 09/11/2003 | US20030171314 Early protection of susceptible animals against foot and mouth disease (FMD) may be achieved by inoculating the animals with a vaccine comprising an interferon DNA sequence. One day after inoculation, animals have been found protected from |
| 09/11/2003 | US20030171309 Pharmaceutically active pyrrolidine derivatives as bax inhibitors |
| 09/11/2003 | US20030171307 Equilibrium mixture of azalide isomers, water, and one or more acids, and methods for preparing such compositions, are disclosed. The antibiotic compositions can be advantageously stabilized by adding one or more water-miscible co-solvents |
| 09/11/2003 | US20030171304 Pyridine-2-yl-aminoalkyl carbonyl glycyl-$g(b)-alanine and derivatives thereof |
| 09/11/2003 | US20030171290 Methods to determine peptides presented on the surface of mammalian cells following addition to the cells of a protein. The present invention also relates to diagnostic tests based on the determination of such peptides or modified molecules |
| 09/11/2003 | US20030171281 Therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, in the treatment of microorganism-caused infections, which infections may be systemic, such as a |
| 09/11/2003 | US20030171276 Capable of inhibiting the binding of hepatitis virus and a target cell, thereby preventing or treating chronic hepatitis; and a fusion interferon capable of still more improving a viral clearance ratio at the termination of |
| 09/11/2003 | US20030171274 Antimicrobial proteins |
| 09/11/2003 | US20030171267 Albumin fusion proteins |
| 09/11/2003 | US20030171254 Purified outer membrane protein of a Moraxella strain, particularly M. catarrhalis, having a molecular mass of about 200 kDa, is provided. The about 200 kDa outer membrane protein as well as nucleic acid molecules encoding the same are useful |
| 09/11/2003 | US20030170872 Mutagenic nucleoside analogs for the treatment of viral disease |
| 09/11/2003 | US20030170870 For broad use in therapy and prevention including antisense agents and vaccines |
| 09/11/2003 | US20030170859 Gene expression inhibition; for treatment of inflammatory, neurological, cardiovascular, and neoplastic tisssue growth disorders |
| 09/11/2003 | US20030170831 Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same |
| 09/11/2003 | US20030170812 Interleukin-1beta converting enzyme like cysteine protease |
| 09/11/2003 | US20030170782 Proteins |
| 09/11/2003 | US20030170662 Screening bactericides, herbicides, malaria drugs using enzymes |
| 09/11/2003 | US20030170657 Protein; inducting antibodies; gene expression; diagnosis, vaccines |
| 09/11/2003 | US20030170648 Autoimmune diseases; inflammatory bowel disease; multiple sclerosis; rheumatic diseases; modulate gene expression |
| 09/11/2003 | US20030170643 Regulation of apoB treatment and drug screening for cardiovascular and metabolic disorders or syndromes |
| 09/11/2003 | US20030170616 Diagnosis using antibodies; genetic engineering |
| 09/11/2003 | US20030170334 Use of Emu Oil and its various fractions as a carrier for antifungal, antibacterial, and antiviral medications & preparations |
| 09/11/2003 | US20030170322 Throat care agents |
| 09/11/2003 | US20030170315 Bioactivation of iron salt, especially an ferric ferrous salt, by adding a magnesium salt (MgCl2); useful as a medicine to treat diseases such as diabetes, freshness preservative agent, and animal and plant growth promoter |
| 09/11/2003 | US20030170274 Activation of HCV-specific T cells |
| 09/11/2003 | US20030170273 Type 1 interferon inducers, such as double-stranded RNA, in combination with antigen delivery systems and/or immunostimulatory molecules for enhancing the immune response of a coadministered antigen |
| 09/11/2003 | US20030170272 EIA vaccine and diagnostic |
| 09/11/2003 | US20030170270 Nucleic acid encoding an infectious, nonpathogenic PCV1, which contains an immunogenic open reading frame gene of a pathogenic PCV2 in place of an ORF gene of the PCV1 nucleic acid molecule. |
| 09/11/2003 | US20030170269 Vaccine for mystery swine disease and method for diagnosis thereof |
| 09/11/2003 | US20030170268 Administering a fusion protein of a heat shock protein or immunostimulatory fragment and a human papilloma virus protein or an antigenic fragment; or a nucleic acid coding the fusion protein |
| 09/11/2003 | US20030170264 Stabilisation of plasmid inheritance in bacteria |
| 09/11/2003 | US20030170263 Expression system |
| 09/11/2003 | US20030170262 Immunogenic detoxified mutant E. coli LT-A toxin |
| 09/11/2003 | US20030170259 Chlamydia antigens and corresponding dna fragments and uses thereof |
| 09/11/2003 | US20030170248 Constant region contains a human immunoglobulin and variable region contains a non-human immunoglobulin variable region; especially treating an infection caused by Enterohemorrhagic Escherichia coli |
| 09/11/2003 | US20030170218 Fungicide and method for producing the same |
| 09/11/2003 | US20030170217 Bifidobacterium in the treatment of inflammatory disease |
| 09/11/2003 | US20030170211 For delivering alphavirus replicon DNA into an animal or animal cells with the replicon encoding one or more heterologous genes to be expressed in the animal or the animal cells |
| 09/11/2003 | US20030170184 Administering to a mammal in need of such treatment a lactic bacteria strain that is exogenous to oral microflora, which strain is selected for its ability to adhere to teeth pellicle and to produce a growth inhibition factor |
| 09/11/2003 | US20030170178 For therapy and diagnosis of infectious diseases; diseases characterised by cellular hyperproliferation such as tumours, psoriasis, actinic keratosis, atheromas, endoarterial hyperplasia, prostate hyperplasia; for sterilization of blood |
| 09/11/2003 | US20030170174 For therapy of diseases, such as parasitic and viral infections, conditions associated with inflammation and infection, and conditions mediated by cell-proliferation or collagen formation; contrast agents |
| 09/10/2003 | EP1343013A1 Methods of screening apoptosis modulating compounds, compounds identified by said methods and use of said compounds as therapeutic agents. |
| 09/10/2003 | EP1342795A2 Method of detecting a variant of gh1 as indicator of growth hormone dysfunction |
| 09/10/2003 | EP1341920A2 Human elongase genes and uses thereof |